Reclast (Zoledronic Acid) vs Evenity (Romosozumab): Long-Term Durability of Response

How Each Drug Works and Why That Determines Durability

Zoledronic acid and romosozumab act through entirely different mechanisms, and those mechanisms directly explain every durability difference seen in clinical trials.

Zoledronic acid is a third-generation bisphosphonate. After a single 5 mg IV infusion, it binds tightly to hydroxyapatite on bone surfaces and inhibits farnesyl pyrophosphate synthase inside osteoclasts, suppressing bone resorption for 12 months or longer per dose [1]. Because the drug embeds physically into bone matrix, it continues releasing slowly for years, which accounts for its prolonged off-drug effect.

Romosozumab is a monoclonal antibody targeting sclerostin, a protein secreted by osteocytes that normally brakes bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation and decreases resorption. This dual action is unique among approved osteoporosis drugs [2]. The trade-off: once the antibody clears the body after the 12-month treatment window ends, sclerostin rebounds, osteoblast activity falls, and any BMD gains begin to reverse unless an antiresorptive is started immediately.

The Biology of Persistence

For zoledronic acid, persistence follows drug pharmacokinetics. The skeleton acts as a depot. Studies measuring urinary N-telopeptide of type I collagen (NTX), a bone resorption marker, show suppression sustained for 3 to 5 years after the last annual dose in some patients [3].

For romosozumab, persistence is entirely dependent on what comes next. A 2021 analysis of FRAME extension data found that lumbar spine BMD gained during 12 months of romosozumab fell back toward baseline within 12 months when patients received placebo rather than denosumab after treatment ended [4]. The molecule itself is gone; without a successor drug to hold the new bone, osteoclasts reclaim it.

Clinical Implication

Think of zoledronic acid as a slow-release reservoir and romosozumab as a construction crew that leaves when the contract expires. Both analogies underscore why treatment sequencing matters more for romosozumab than for any other approved agent.

HORIZON-PFT: What the Gold-Standard Zoledronic Acid Trial Actually Showed

The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Key Fracture Trial (HORIZON-PFT, N=7,765) remains the definitive evidence base for zoledronic acid [1]. Published in the New England Journal of Medicine in 2007, the trial assigned postmenopausal women with osteoporosis to 5 mg IV zoledronic acid or placebo once yearly for 3 years.

Primary Fracture Outcomes

At 36 months, zoledronic acid reduced vertebral fracture risk by 70% (3.3% vs 10.9% in placebo, P<0.001) [1]. Hip fracture risk fell by 41% (1.4% vs 2.5%, P=0.002) [1]. Non-vertebral fracture risk dropped 25% (P<0.001).

The Extension Data: Durability Without Re-dosing

HORIZON-PFT included a 3-year extension (HORIZON-EXT) in which patients who had received 3 years of zoledronic acid were re-randomized to 3 more years of drug or placebo. Among those who stopped after 3 years, lumbar spine BMD declined modestly but remained significantly above pre-treatment levels at year 6. Vertebral fracture risk in the discontinued group was not significantly different from those who continued for all 6 years [3].

This is the clinical basis for the widely cited "drug holiday" concept for zoledronic acid. After 3 annual infusions in patients at moderate fracture risk, a 3-year pause is generally acceptable per Endocrine Society and American Association of Clinical Endocrinology (AACE) guidance, provided bone turnover markers are monitored [5].

Mortality Signal

HORIZON-PFT also documented a 28% reduction in all-cause mortality with zoledronic acid (9.6% vs 13.3%, P=0.01) in a post-hip-fracture subgroup [6]. No comparable mortality benefit has been demonstrated for romosozumab.

ARCH: Romosozumab's Key Trial and What Durability Actually Looks Like

The Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk (ARCH, N=4,093) compared 12 months of romosozumab 210 mg SC monthly followed by 12 months of alendronate versus alendronate alone for 24 months in postmenopausal women with osteoporosis and a prior vertebral fracture [2].

Fracture Outcomes

At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% vs alendronate alone (6.2% vs 11.9%, P<0.001) [2]. Clinical fractures fell 27% and hip fractures 38% compared with alendronate alone over 24 months.

BMD Gains: Speed Matters

At 12 months (end of romosozumab phase), lumbar spine BMD had increased by 13.7% from baseline in the romosozumab group versus 5.0% in the alendronate group [2]. Total hip BMD rose 6.2% vs 2.8%. These are the largest first-year BMD gains of any approved osteoporosis therapy.

What Happens After Romosozumab Stops

After the 12-month romosozumab phase in ARCH, all patients transitioned to alendronate. BMD continued to rise in the romosozumab-to-alendronate group through month 24, but the rate of gain slowed substantially. The critical point: patients who received placebo instead of alendronate after romosozumab in the FRAME trial lost nearly all vertebral BMD gains within 12 months [4]. ARCH did not include a no-treatment arm after romosozumab, but the FRAME placebo data make the message clear.

The Cardiovascular Black-Box Warning

ARCH revealed a higher rate of serious cardiovascular events in the romosozumab arm: 2.5% vs 1.9% for alendronate (P=0.07 at that interim, but sufficient for FDA labeling action) [2]. The FDA issued a boxed warning for myocardial infarction and stroke. Romosozumab is contraindicated within the preceding 12 months of MI or stroke.

The Endocrine Society's 2020 clinical practice guideline states: "Romosozumab should not be used in patients with a history of myocardial infarction or stroke within the preceding year." [5]

Head-to-Head Durability Comparison: The Data Side by Side

No randomized controlled trial has directly compared zoledronic acid with romosozumab as stand-alone agents for durability. The available evidence must be assembled from separate trials, extension studies, and indirect comparisons.

BMD Trajectory Over 5 Years

In HORIZON-PFT, 3 years of annual zoledronic acid produced lumbar spine BMD gains of roughly 6.7% from baseline [1]. In HORIZON-EXT, those gains were largely maintained through year 6 even with a 3-year pause [3].

In ARCH, 12 months of romosozumab produced 13.7% lumbar spine BMD gain [2]. After transition to alendronate, gains continued to accumulate through month 24. Without antiresorptive follow-on, FRAME data suggest 50 to 75% of vertebral BMD gain is lost within 12 months [4].

The practical summary: romosozumab builds more bone faster but requires mandatory antiresorptive sequencing. Zoledronic acid builds less bone per year but sustains it with minimal patient burden.

Fracture Reduction Over Time

| Outcome | Zoledronic Acid (HORIZON-PFT) | Romosozumab then Alendronate (ARCH) | |---|---|---| | Vertebral fracture reduction | 70% vs placebo at 36 months | 48% vs alendronate at 24 months | | Hip fracture reduction | 41% vs placebo at 36 months | 38% vs alendronate at 24 months | | Durability off-drug | BMD stable up to 3 years after stopping | BMD lost within 12 months without follow-on | | CV risk | No boxed warning | Boxed warning: MI and stroke |

Bone Turnover Markers

Zoledronic acid suppresses serum C-telopeptide (CTX) by approximately 50 to 60% within 3 months of infusion and keeps it suppressed for 12 months [1]. Romosozumab suppresses CTX by roughly 15 to 20% while simultaneously elevating P1NP (a bone formation marker) by 145% at month 1 [2]. After romosozumab stops, CTX rebounds above baseline within 3 to 6 months in the absence of antiresorptive therapy, driving the BMD loss seen in FRAME.

A Clinical Decision Framework for Choosing Between the Two

Use zoledronic acid first when:

• The patient has moderate-to-high fracture risk but no prior vertebral fracture
• Cardiovascular history includes MI or stroke within 12 months (romosozumab is contraindicated)
• The treatment goal is 3 to 6 years of adherence-friendly, once-yearly dosing
• Prior oral bisphosphonate use has established tolerability of the drug class

Use romosozumab first when:

• The patient has very high fracture risk, defined by the AACE as a T-score of -3.0 or below, or two or more prior vertebral fractures [5]
• Rapid BMD accrual is needed (e.g., long-term glucocorticoid use, prior denosumab discontinuation with rebound)
• The plan includes a clear, pre-committed transition to zoledronic acid or denosumab at month 12

Sequence romosozumab then zoledronic acid when:

• Maximum anabolic effect is needed first, followed by durable antiresorptive consolidation
• The patient cannot tolerate oral bisphosphonates and prefers annual IV infusion to monthly SC injection

Switching from Reclast (Zoledronic Acid) to Evenity (Romosozumab)

This sequencing direction, antiresorptive to anabolic, is biologically suboptimal and is not recommended by current guidelines without a compelling reason.

Why Antiresorptive-to-Anabolic Switching Is Problematic

Bisphosphonates suppress bone turnover. Romosozumab's anabolic effect depends on active osteoblast function. When bone turnover is already suppressed by zoledronic acid, the anabolic response to romosozumab may be blunted. A 2021 post-hoc analysis published in the Journal of Bone and Mineral Research found that prior bisphosphonate use was associated with attenuated P1NP responses to romosozumab, suggesting reduced anabolic signal [7]. The BMD gains seen in treatment-naive patients in ARCH or FRAME may not be replicated in patients switching from zoledronic acid.

When Switching May Still Be Considered

Some patients on long-term zoledronic acid continue to fracture despite therapy, or experience progressive BMD decline after the recommended 3-year zoledronic acid treatment period. In these scenarios, a specialist may consider switching to romosozumab after a drug holiday of 12 to 18 months to allow some recovery of bone turnover [5].

The More Common and Evidence-Supported Direction

The ARCH trial established the romosozumab-to-alendronate (or zoledronic acid) sequence as the high-efficacy standard. Starting with romosozumab for 12 months, then transitioning to annual zoledronic acid, consolidates anabolic gains with durable antiresorptive protection. This sequence is endorsed in the AACE 2020 postmenopausal osteoporosis guidelines [5].

Safety Profiles and Long-Term Monitoring Requirements

Zoledronic Acid: Established Long-Term Safety Record

After over 18 years of post-marketing experience, zoledronic acid's safety profile is well characterized. Acute phase reactions (flu-like symptoms, fever, myalgia) occur in approximately 30% of patients after the first infusion and decline sharply with subsequent doses [1]. Osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF) are rare: ONJ incidence is estimated at 1 in 10,000 to 1 in 100,000 patient-years in osteoporosis dosing (not oncology dosing) [8]. Renal function must be checked before each infusion; the drug is contraindicated when creatinine clearance falls below 35 mL/min.

After 3 to 5 years of therapy, AACE and Endocrine Society guidelines recommend reassessment for AFF risk, particularly in patients with thigh pain. A drug holiday is appropriate for patients at moderate post-treatment risk, with resumption triggered by declining BMD or new fracture [5].

Romosozumab: The Cardiovascular Signal and Dental Requirements

The boxed warning for MI and stroke is the defining safety constraint for romosozumab. In ARCH, the absolute risk difference was 0.6 percentage points over 12 months [2]. Patients must have a full cardiovascular risk assessment before starting. ONJ and AFF risks are present but appear low based on 12 months of treatment duration in current trials. Dental evaluation before starting is standard of care, identical to bisphosphonate protocols.

Calcium (1,000 mg daily) and vitamin D (800 to 1,000 IU daily) supplementation is required during romosozumab therapy. Hypocalcemia has been reported, particularly in patients with vitamin D deficiency at baseline [2].

Monitoring Schedule Comparison

| Parameter | Zoledronic Acid | Romosozumab | |---|---|---| | Renal function | Before each infusion | Baseline only (no renal restriction at osteoporosis dose) | | Dental evaluation | Before starting | Before starting | | CV risk assessment | Not required | Required; contraindicated with recent MI/stroke | | Bone turnover markers | At 3 months post-infusion | At 1 and 6 months | | DXA BMD | Every 1-2 years | At 12 months (end of treatment) | | Calcium/vitamin D | Required | Required |

Regulatory Approvals and Labeled Indications

Zoledronic acid (Reclast) received FDA approval for postmenopausal osteoporosis in 2007 and for glucocorticoid-induced osteoporosis in 2011 [9]. The labeled indication also covers osteoporosis in men.

Romosozumab (Evenity) received FDA approval in April 2019 for postmenopausal women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or failure or intolerance to other available osteoporosis therapy [10]. Romosozumab is not approved for men or for glucocorticoid-induced osteoporosis as of 2025.

The labeled treatment duration for romosozumab is 12 months. Retreatment data do not exist in regulatory submissions, and re-use after a first course is not currently supported by guideline recommendations.

Practical Patient Scenarios

Scenario 1: The 68-Year-Old With a Single Vertebral Fracture and No Cardiac History

Romosozumab for 12 months followed by zoledronic acid annually is the evidence-supported choice. ARCH showed a 48% reduction in new vertebral fractures with this sequence vs alendronate alone [2]. The anabolic phase rebuilds trabecular architecture rapidly, and zoledronic acid consolidates those gains for years.

Scenario 2: The 72-Year-Old With Prior MI and T-Score -2.8

Romosozumab is contraindicated. Zoledronic acid 5 mg IV annually for 3 years, with reassessment at year 3, is the appropriate choice. HORIZON-PFT supports strong vertebral and hip fracture reduction in this profile [1].

Scenario 3: The 65-Year-Old Who Has Received 5 Years of Annual Zoledronic Acid and Is Now on a Drug Holiday

Bone turnover markers should be checked 6 to 12 months into the holiday. If CTX rises above the premenopausal reference range or BMD declines more than 5% at the hip, resuming zoledronic acid or transitioning to romosozumab (with CV clearance and after bone turnover has partially recovered) are both options worth specialist review.

Cost and Access Considerations

Zoledronic acid became available in generic form in the United States after 2015. As of 2024, generic zoledronic acid infusion costs range from approximately $200 to $500 per infusion before insurance, making it one of the most cost-effective injectable osteoporosis therapies available [11].

Romosozumab (Evenity) remains branded. A 12-month course carries a list price exceeding $20,000, though manufacturer patient assistance programs and payer step-therapy criteria significantly affect out-of-pocket costs. Most commercial insurers require a prior-authorization with documentation of high fracture risk or prior therapy failure.